GlassScriptPhysician profile
Scott T Hamler
NPI 1538178298
$952.77
in general payments reported to CMS, 2019-2025
22 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.80 · 2023: $37.17 · 2024: $253 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $143.92 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $142.04 | 2024-2025 | Breztri, Airsupra |
| Gilead Sciences, INC. | $88.34 | 2022-2025 | |
| Novo Nordisk INC | $58.91 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $56.83 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $44.41 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.37 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $40.93 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $37.31 | 2024 | Gemtesa |
| Viiv Healthcare Company | $37.16 | 2023-2024 | Apretude |
| Glaxosmithkline, LLC. | $36.64 | 2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $30.90 | 2025 | Veozah |
| Abbott Laboratories | $27.40 | 2025 | Id Now Instrument |
| Azurity Pharmaceuticals, INC. | $24.50 | 2025 | Azmiro |
| Inspire Medical Systems, INC. | $21.56 | 2025 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $21.15 | 2025 | |
| Pfizer INC. | $20.48 | 2025 | |
| Paratek Pharmaceuticals, INC. | $20.38 | 2025 | Xhance, Nuzyra |
| Dynavax Technologies Corporation | $15.54 | 2025 | Heplisav-B |
| Vertex Pharmaceuticals Incorporated | $15.48 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.81 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $12.71 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hamler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.